Results 181 to 190 of about 5,547 (244)

Barriers to adoption of biosimilar insulins in Europe: A mixed-methods study. [PDF]

Diabetes Obes Metab
Car E, Habets G, Vulto AG, Heinemann L, Huys I, Simoens S.   +5 more
europepmc   +1 more source

Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer. [PDF]

Breast Cancer Res Treat
Alonso-Romero JL, Martínez-García J, Carrillo-Vicente R, Aramburo AF, Díez AF, Henarejos PS, de la Morena Barrio P, Boix AP, Jiménez MD, Siles JP, Maestre JAP, de Las Heras-Rubio A, Carreño PR.   +12 more
europepmc   +1 more source

Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings. [PDF]

BioDrugs
Kvien TK, Betteridge N, Brückmann I, Bodenmüller W, Bryn G, Danese S, Gonçalves J, Maravic Z, Thorne C, Wingate L, Cornes P.   +10 more
europepmc   +1 more source

Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study. [PDF]

Sci Rep
Song JR, Park UC, Lee CS, Cho JJ, Kim JY, Baek SC, Jeong A, Sharma A, Kim JH, Sagong M, Woo SJ, International Retina Biosimilar Study Group (Inter BIOS Group).   +11 more
europepmc   +1 more source

State Substitution Laws and Uptake of an Interchangeable Insulin Biosimilar.

JAMA Health Forum
Kwon Y, Sarpatwari A, Dusetzina SB.
europepmc   +1 more source

A comparison of JC virus assay performance provided with originator and biosimilar natalizumab. [PDF]

Mult Scler
Varley J, Beyrouti R, Nicholas R, Dorsey R, Brownlee W, Paling D, Mathews J, Dobson R.   +7 more
europepmc   +1 more source

The Role of Outcome Response Rate in Planning Biosimilar Studies Using Different Evaluation Metrics. [PDF]

Pharmaceuticals (Basel)
Cen L, Arani R, Tang D.
europepmc   +1 more source

Using machine learning algorithms to optimize treatment with high-cost biologics in a national cohort of patients with inflammatory bowel disease. [PDF]

JAMIA Open
Hou JK, Tang TM, Sansgiry S, Van T, Richardson PA, Pham C, Cunningham F, Baker JA, Zhu J, Waljee AK.   +9 more
europepmc   +1 more source

Biosimilars and reference biological medicines in the treatment of rheumatoid arthritis: a multicenter cross-sectional study in Catalonia, Spain. [PDF]

Clin Rheumatol
Mas Marin J, Molina-Olano M, Sola NR, Miserachs-Aranda N, Montoliu Alcón P, De Pourcq JT, Quiñones Ribas C, Borràs Trias L, Fernández-Cañabate E, González-Valdivieso J, Figueiredo-Escribá C, Delgado-Hernández R, Braza AJ, Lastra CF, Mariño EL, Modamio P.   +15 more
europepmc   +1 more source

Comparative Forced Degradation Study of Anticomplement C5 Biosimilar and Originator Monoclonal Antibodies. [PDF]

Pharmaceuticals (Basel)
Celik Yamaci M, Pamukcu C, Erdemgil Y, Atik AE, Keles ZZY, Can O.   +5 more
europepmc   +1 more source